Initiator Pharma A/S (INIT.ST)
SEK 7.0
(-1.41%)
SEK 7.0
(-1.41%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 29.78 Million DKK | -38.39% |
| 2022 | 48.34 Million DKK | -9.97% |
| 2021 | 53.7 Million DKK | 244.17% |
| 2020 | 15.6 Million DKK | 36.41% |
| 2019 | 11.43 Million DKK | -33.99% |
| 2018 | 17.32 Million DKK | 86.36% |
| 2017 | 9.29 Million DKK | 1551.51% |
| 2016 | 563 Thousand DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 24.35 Million DKK | -18.24% |
| 2024 Q2 | 20.22 Million DKK | -16.94% |
| 2023 Q1 | 39.55 Million DKK | -18.18% |
| 2023 FY | 29.78 Million DKK | -38.39% |
| 2023 Q4 | 29.78 Million DKK | 9.11% |
| 2023 Q3 | 27.29 Million DKK | -13.44% |
| 2023 Q2 | 31.53 Million DKK | -20.27% |
| 2022 Q2 | 35.45 Million DKK | -4.87% |
| 2022 Q3 | 53.08 Million DKK | 49.7% |
| 2022 FY | 48.34 Million DKK | -9.97% |
| 2022 Q4 | 48.34 Million DKK | -8.92% |
| 2022 Q1 | 37.27 Million DKK | -30.59% |
| 2021 FY | 53.7 Million DKK | 244.17% |
| 2021 Q2 | 32.97 Million DKK | 153.09% |
| 2021 Q3 | 55.01 Million DKK | 66.83% |
| 2021 Q4 | 53.7 Million DKK | -2.38% |
| 2021 Q1 | 13.02 Million DKK | -16.5% |
| 2020 Q2 | 8.27 Million DKK | -9.06% |
| 2020 Q3 | 8.26 Million DKK | -0.07% |
| 2020 FY | 15.6 Million DKK | 36.41% |
| 2020 Q4 | 15.6 Million DKK | 88.78% |
| 2020 Q1 | 9.09 Million DKK | -20.48% |
| 2019 Q2 | 14.14 Million DKK | -11.62% |
| 2019 FY | 11.43 Million DKK | -33.99% |
| 2019 Q3 | 14.79 Million DKK | 4.57% |
| 2019 Q4 | 11.43 Million DKK | -22.69% |
| 2019 Q1 | 16 Million DKK | -7.61% |
| 2018 Q1 | 4.45 Million DKK | -52.13% |
| 2018 FY | 17.32 Million DKK | 86.36% |
| 2018 Q4 | 17.32 Million DKK | 101.46% |
| 2018 Q3 | 8.6 Million DKK | -29.29% |
| 2018 Q2 | 12.16 Million DKK | 173.26% |
| 2017 Q1 | 13.31 Million DKK | 2265.36% |
| 2017 Q4 | 9.29 Million DKK | -16.83% |
| 2017 Q3 | 11.17 Million DKK | -8.08% |
| 2017 FY | 9.29 Million DKK | 1551.51% |
| 2017 Q2 | 12.16 Million DKK | -8.67% |
| 2016 Q4 | 563 Thousand DKK | 0.0% |
| 2016 FY | 563 Thousand DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 74.854% |
| Ziccum AB (publ) | 14.97 Million SEK | -98.945% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -48.625% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.489% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 52.248% |
| Mendus AB (publ) | 755.95 Million SEK | 96.06% |
| Genovis AB (publ.) | 288.85 Million SEK | 89.688% |
| Intervacc AB (publ) | 259.61 Million SEK | 88.527% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 29.012% |
| Active Biotech AB (publ) | 44 Million SEK | 32.305% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 89.314% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 52.076% |
| Aptahem AB (publ) | 63.02 Million SEK | 52.739% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 93.998% |
| Kancera AB (publ) | 65.64 Million SEK | 54.624% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 91.522% |
| Fluicell AB (publ) | 9.34 Million SEK | -218.908% |
| Saniona AB (publ) | 64.14 Million SEK | 53.563% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 11.356% |
| Biovica International AB (publ) | 131.4 Million SEK | 77.333% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 43.784% |
| AcouSort AB (publ) | 34.51 Million SEK | 13.696% |
| Xintela AB (publ) | 18.39 Million SEK | -61.924% |
| Abliva AB (publ) | 87.49 Million SEK | 65.958% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 96.082% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.633% |
| OncoZenge AB (publ) | 20.34 Million SEK | -46.441% |
| Amniotics AB (publ) | 26.08 Million SEK | -14.184% |
| 2cureX AB (publ) | 16.62 Million SEK | -79.164% |
| CombiGene AB (publ) | 120.61 Million SEK | 75.304% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -390.143% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.433% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.439% |
| Corline Biomedical AB | 100.1 Million SEK | 70.245% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 83.183% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 78.815% |
| I-Tech AB | 152.44 Million SEK | 80.461% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 97.074% |
| Cyxone AB (publ) | 43.65 Million SEK | 31.77% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 62.149% |
| Biosergen AB | 7.2 Million SEK | -313.637% |
| Cantargia AB (publ) | 223.71 Million SEK | 86.686% |
| NextCell Pharma AB | 81.28 Million SEK | 63.357% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 96.108% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 1.283% |
| Nanologica AB (publ) | 77.42 Million SEK | 61.531% |
| SynAct Pharma AB | 228.01 Million SEK | 86.937% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -11.295% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -37.244% |
| LIDDS AB (publ) | 17.65 Million SEK | -68.711% |
| Lipum AB (publ) | 12.11 Million SEK | -145.962% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 97.873% |
| Alzinova AB (publ) | 123.18 Million SEK | 75.821% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 87.505% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -252.289% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 65.051% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -100.323% |
| Simris Alg AB (publ) | 174.55 Million SEK | 82.936% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 86.276% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 95.442% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 65.792% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -4.483% |